MIRM Mirum Pharmaceuticals, Inc.
Stock · NasdaqGM · United States · Healthcare · US6047491013
NowoTrade is an independent information site. It is not affiliated with, endorsed by or sponsored by Mirum Pharmaceuticals, Inc., and has no access to any account you may have with it. The name and the logo belong to their owners.
Price
93.72 USD
+0.19%
52-week range
63.23 – 130.00
Dividend yield—
Market cap6.1B
NowoTrade score
32 Grade A
Price history
Daily prices in USD.
Updated 07 Nov 2026 09:50. Information, not advice.
Results
Next results
24 Feb 2027
in 109 days · 16:00 · estimate -0.44
Last results
-0.42 vs -0.41 estimated
03 Nov 2026 · In line -0.3%
Beat the estimate
3 of 12
8 missed · 1 in line
Average surprise
-55.9%
reported against the estimate, last 12 quarters
Earnings per share: estimate and reported
Estimate Reported: beat Reported: miss In line
Quarterly results
| Date | EPS estimate | EPS reported | Surprise | Result |
|---|---|---|---|---|
| 24 Feb 2027 16:00 | -0.44 | — | — | Upcoming |
| 03 Nov 2026 16:00 | -0.41 | -0.42 | -0.3% | In line |
| 05 Aug 2026 16:00 | -0.75 | -0.80 | -7.4% | Miss |
| 06 May 2026 16:00 | -0.35 | -1.08 | -205.6% | Miss |
| 25 Feb 2026 16:00 | 0.06 | -0.12 | -308.7% | Miss |
| 04 Nov 2025 16:00 | -0.16 | 0.05 | +131.5% | Beat |
| 06 Aug 2025 16:00 | -0.33 | -0.12 | +64.1% | Beat |
| 07 May 2025 16:00 | -0.27 | -0.30 | -9.7% | Miss |
| 26 Feb 2025 16:00 | -0.25 | -0.49 | -98.7% | Miss |
| 12 Nov 2024 08:00 | -0.45 | -0.30 | +33.0% | Beat |
| 07 Aug 2024 16:00 | -0.46 | -0.52 | -12.3% | Miss |
| 08 May 2024 16:00 | -0.30 | -0.54 | -77.3% | Miss |
| 28 Feb 2024 16:00 | -0.22 | -0.63 | -180.1% | Miss |
| 02 Nov 2023 16:00 | -0.81 | -0.57 | +29.6% | Beat |
| 03 Aug 2023 16:00 | -0.79 | -0.65 | +16.7% | Beat |
| 04 May 2023 16:00 | -0.97 | -0.80 | +17.7% | Beat |
| 08 Mar 2023 16:00 | -0.92 | -0.99 | -7.3% | Miss |
| 09 Nov 2022 07:00 | -1.08 | -1.02 | +6.0% | Beat |
| 04 Aug 2022 16:00 | -1.06 | -0.84 | +20.8% | Beat |
| 05 May 2022 16:00 | -1.38 | -1.17 | +15.2% | Beat |
| 09 Mar 2022 16:00 | 1.84 | -1.61 | -187.9% | Miss |
| 15 Nov 2021 16:00 | -1.50 | -1.60 | -6.7% | Miss |
| 05 Aug 2021 16:00 | -1.08 | -1.45 | -34.6% | Miss |
| 06 May 2021 16:00 | -0.98 | -1.68 | -70.6% | Miss |
| 09 Mar 2021 16:00 | -0.98 | -1.43 | -45.5% | Miss |
| 12 Nov 2020 06:00 | -0.98 | -0.86 | +12.5% | Beat |
| 06 Aug 2020 16:00 | -0.87 | -0.93 | -6.5% | Miss |
| 07 May 2020 16:00 | -0.84 | -0.86 | -2.8% | Miss |
| 12 Mar 2020 16:00 | -0.85 | -0.79 | +6.7% | Beat |
| 06 Nov 2019 16:00 | -0.63 | -0.84 | -34.2% | Miss |
| 28 Aug 2019 16:00 | -0.59 | -0.59 | +0.5% | In line |
Annual results · USD
| Year | Revenue | Change | Net income | Net margin | EPS | EPS change | Free cash flow |
|---|---|---|---|---|---|---|---|
| 2025 | 521.3M | +54.7% | -23.4M | -4.5% | -0.47 | +74.6% | 54.9M |
| 2024 | 336.9M | +80.8% | -87.9M | -26.1% | -1.85 | +53.0% | -10.7M |
| 2023 | 186.4M | +141.8% | -163.4M | -87.7% | -3.94 | +2.0% | -91.1M |
| 2022 | 77.1M | — | -135.7M | -176.0% | -4.02 | — | -120.4M |
| 2021 | — | — | — | — | — | — | — |
Dates and earnings per share from the company reports as collected by the data provider; the estimate is the analysts' average before the report. Information, not advice.
Prices by day, week and month
| Period | Opening price | High | Low | Closing price | Change | Volume | Dividend |
|---|---|---|---|---|---|---|---|
| 26 Jan 2022 | 17.87 | 18.41 | 17.04 | 17.61 | -0.62% | 1,032,200 | |
| 25 Jan 2022 | 17.50 | 17.81 | 16.99 | 17.72 | +0.68% | 104,300 | |
| 24 Jan 2022 | 16.52 | 17.95 | 16.07 | 17.60 | +4.14% | 250,500 | |
| 21 Jan 2022 | 17.65 | 17.87 | 16.73 | 16.90 | -5.38% | 134,600 | |
| 20 Jan 2022 | 18.28 | 18.79 | 17.84 | 17.86 | -1.81% | 127,100 | |
| 19 Jan 2022 | 18.34 | 18.53 | 18.01 | 18.19 | -0.93% | 88,300 | |
| 18 Jan 2022 | 18.50 | 18.94 | 18.07 | 18.36 | -2.03% | 197,000 | |
| 14 Jan 2022 | 18.00 | 18.78 | 17.84 | 18.74 | +4.34% | 185,600 | |
| 13 Jan 2022 | 17.54 | 18.35 | 17.30 | 17.96 | +2.45% | 212,300 | |
| 12 Jan 2022 | 17.11 | 17.82 | 16.67 | 17.53 | +10.11% | 224,200 | |
| 11 Jan 2022 | 15.36 | 15.99 | 14.63 | 15.92 | +2.71% | 110,400 | |
| 10 Jan 2022 | 15.35 | 15.67 | 15.10 | 15.50 | -0.39% | 54,000 | |
| 07 Jan 2022 | 15.82 | 16.10 | 15.50 | 15.56 | -1.95% | 70,700 | |
| 06 Jan 2022 | 15.65 | 16.03 | 15.25 | 15.87 | +0.83% | 57,200 | |
| 05 Jan 2022 | 16.55 | 16.83 | 15.62 | 15.74 | -5.18% | 75,100 | |
| 04 Jan 2022 | 16.37 | 16.71 | 16.19 | 16.60 | +1.47% | 124,000 | |
| 03 Jan 2022 | 15.93 | 16.51 | 15.58 | 16.36 | +2.57% | 97,900 | |
| 31 Dec 2021 | 15.72 | 16.16 | 15.53 | 15.95 | +1.53% | 78,500 | |
| 30 Dec 2021 | 15.69 | 16.29 | 15.49 | 15.71 | -0.13% | 55,300 | |
| 29 Dec 2021 | 15.87 | 15.97 | 15.41 | 15.73 | -1.26% | 65,300 | |
| 28 Dec 2021 | 15.66 | 16.35 | 15.66 | 15.93 | +1.59% | 91,400 | |
| 27 Dec 2021 | 15.65 | 15.94 | 15.17 | 15.68 | +0.51% | 108,500 | |
| 23 Dec 2021 | 15.75 | 15.97 | 15.24 | 15.60 | -0.45% | 60,300 | |
| 22 Dec 2021 | 15.69 | 16.00 | 15.10 | 15.67 | -0.13% | 60,900 | |
| 21 Dec 2021 | 15.97 | 16.10 | 15.38 | 15.69 | -0.44% | 164,500 |
Page 49 of 51
Prices in USD, adjusted for splits but not for dividends. Weeks run Monday to Friday and months follow the calendar; the change compares each close with the previous period's. Dividends are those whose ex-dividend date falls in the period, per share. Information, not advice.
News
- GeneDx and Mirum to provide genetic tests for cholestasis, cataracts or PBD-ZSD (opens in a new tab) Medical Device Network · 06 Nov 2026 11:03
- Leerink Partners Maintains Outperform on Mirum Pharmaceuticals, Lowers Price Target to $140 (opens in a new tab) Benzinga · 05 Nov 2026 17:23
- GeneDx and Mirum Pharmaceuticals Launch Sponsored Testing Programs to Help Patients Find Answers Through Comprehensive Genetic Testing (opens in a new tab) 05 Nov 2026 13:30
- Why Mirum Pharmaceuticals (MIRM) Is Up 11.4% And What's Next After Earnings Beat (opens in a new tab) Simply Wall St. · 05 Nov 2026 04:42
- Mirum (MIRM) Q3 2026 Earnings Call Transcript (opens in a new tab) Motley Fool · 04 Nov 2026 15:29
- Mirum Pharmaceuticals, Inc. Q3 2026 Earnings Call Summary (opens in a new tab) Moby · 04 Nov 2026 13:30
- CORRECTION: RBC Capital Reiterates Outperform on Mirum Pharmaceuticals, Maintains $155 Price Target (opens in a new tab) Benzinga · 04 Nov 2026 13:05
- Citizens Maintains Market Outperform on Mirum Pharmaceuticals, Raises Price Target to $167 (opens in a new tab) Benzinga · 04 Nov 2026 09:47
- HC Wainwright & Co. Maintains Buy on Mirum Pharmaceuticals, Raises Price Target to $202 (opens in a new tab) Benzinga · 04 Nov 2026 08:50
- Cantor Fitzgerald Maintains Overweight on Mirum Pharmaceuticals, Raises Price Target to $160 (opens in a new tab) Benzinga · 04 Nov 2026 08:12
- Mirum Pharmaceuticals Inc (MIRM) Q3 2026 Earnings Call Highlights: Raised Guidance, $500 ... (opens in a new tab) GuruFocus.com · 04 Nov 2026 07:09
- Mirum Pharmaceuticals Q3 Earnings Call Highlights (opens in a new tab) MarketBeat · 04 Nov 2026 02:14
- Mirum Pharmaceuticals, Inc. (MIRM) Q3 2026 Earnings Call Transcript (opens in a new tab) SeekingAlpha · 03 Nov 2026 23:55
- Here's What Key Metrics Tell Us About Mirum Pharmaceuticals (MIRM) Q3 Earnings (opens in a new tab) Zacks · 03 Nov 2026 21:30
- Mirum Pharmaceuticals, Inc. (MIRM) Reports Q3 Loss, Tops Revenue Estimates (opens in a new tab) Zacks · 03 Nov 2026 21:15
Headlines link to the original articles of the publishers shown; NowoTrade does not write, check or endorse them. Only the most relevant news about each company is kept. Information, not advice.
Key data
- Previous close
- 93.54 USD
- Market cap
- 6.1B
- Exchange
- NasdaqGM
- Country
- United States
- Sector
- Healthcare
- Industry
- Biotechnology
- Currency
- USD
Dividends
No dividends on record.
Why this score
| Part of the score | Points | Why |
|---|---|---|
| Business growth Yearly growth of revenue and of earnings per share. | 25.0 / 25 |
|
| Quality Return on equity, net margin and how stable the margins are. | 0.0 / 25 |
|
| Financial strength Net debt against operating earnings, interest cover and free cash flow. | 7.7 / 20 |
|
| Valuation Free cash flow yield and the P/E against its sector. | 5.4 / 15 |
|
| Analysts How far the analysts' average target is from today's price. | 10.0 / 10 |
|
- Score capped at 50: three or more warnings
- Thin interest cover: operating profit is only -1.5× the interest
- The last full year was a loss
- Total debt has risen three years in a row
Growth profile: it pays no dividend, so it is scored on business growth, quality and financial strength. Based on 95% of the figures (grade A). Warnings take 18 points off.
Warnings take points off and some cap the score. In your account the score also considers how the share fits your portfolio.
Figures
| Figure | Value | Reading | Sector median |
|---|---|---|---|
| P/E (forward) | -551.29× | Weak | 14.98× |
| Price / book | -112.78× | Weak | 3.94× |
| Price / sales | 9.12× | Weak | 3.37× |
| EV / EBITDA | -54.84× | Weak | 12.96× |
| Free cash flow yield | 1.6% | Weak | 2.6% |
| Figure | Value | Reading | Sector median |
|---|---|---|---|
| Gross margin | 81.7% | Good | 59.2% |
| Operating margin | -24.9% | Weak | 7.4% |
| Net margin | -134.8% | Weak | 3.4% |
| Return on equity | -760% | Weak | 5.7% |
| Return on assets | -10% | Weak | 3.6% |
| Figure | Value | Reading | Sector median |
|---|---|---|---|
| Revenue growth / year | 89.1% | Good | 10.8% |
| Figure | Value | Reading | Sector median |
|---|---|---|---|
| Debt / equity | 1.02× | Fair | 0.46× |
| Interest cover | -1.54× | Weak | 3.26× |
| Current ratio | 2.07× | Good | 2.35× |
The reading follows general rules of thumb and each sector has its own norms: compare with the sector median when it is shown. Information, not advice.
Follow MIRM and get alerts
Create a free account to add it to your watchlist, set a price alert, see how it fits your portfolio and track your dividends.